Drug intelligence / Profile preview

SENT010

Development stage: Preclinical
Lead developer: Sentio BioSciences

Overview

SENT010 is a preclinical-stage therapeutic candidate being developed by Sentio BioSciences. It is part of the company's pipeline of "Medically Essential Medicines," which focuses on addressing critical gaps in the supply or formulation of essential healthcare products. As of current public disclosures, the specific molecular target, modality, and primary disease indication for SENT010 have not been specified, though it is categorized under the "Medically Essential" program. The program aims to ensure reliable access to critical medications that are often subject to shortages or supply chain vulnerabilities.

Beyond the preview

Go deeper on SENT010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENT010.

Explore the full profile